Dermatose flagellée induite par bléomycine: un nouveau cas Clinique

We report the case of a 56-year old female patient with granulosa tumour of the ovary treated in our institute. She underwent complete resection followed by auxiliary chemotherapy according to BEP protocol (Bleomycine 30 Mg J1, J8 and J15, Etoposide 100mg/m J1-J5, Cisplatine 20 mg/m J1-J5). After her second cycle of BEP regimen, the patient had multiple skin linear hyperpigmentations at the level of the superior anterior and posterior thoracic regions and of the lower back, without pruritus, resembling Bleomycininduced flagellate erythema. These skin lesions occurred despite the use of antihistamine premedication and persisted after treatment discontinuation. Flagellate rash also known as flagellate dermatitis is a complication of Bleomycine therapy in 20% to 30% of cases. Generally, this toxicity occurs after a cumulative dose of 90-285 mg, but some cases were reported at doses of 15 mg. This is a benign disease whose occurrence should not put the continuation of Bleomycin therapy at risk.